350 results on '"Hoschler, Katja"'
Search Results
2. Serum HCoV-spike specific antibodies do not protect against subsequent SARS-CoV-2 infection in children and adolescents
3. Genomic investigations of unexplained acute hepatitis in children
4. Paediatric acute hepatitis of unknown aetiology: a national investigation and adenoviraemia case-control study in the UK
5. Neutralizing antibody activity against 21 SARS-CoV-2 variants in older adults vaccinated with BNT162b2
6. Antibody Persistence After Primary SARS-CoV-2 Infection and Protection Against Future Variants Including Omicron in Adolescents: National, Prospective Cohort Study
7. Antibody persistence and neutralising activity in primary school students and staff: Prospective active surveillance, June to December 2020, England
8. Seasonal trivalent inactivated influenza vaccine with topical imiquimod in immunocompromised patients: A randomized controlled trial
9. Seroprevalence of SARS-CoV-2 antibodies in university students: Cross-sectional study, December 2020, England
10. Seroprevalence of SARS-CoV-2 among Blood Donors and Changes after Introduction of Public Health and Social Measures, London, UK
11. Interim 2023/2024 Season Influenza Vaccine Effectiveness in Primary and Secondary Care in the United Kingdom
12. End of 2022/23 Season Influenza Vaccine Effectiveness in Primary Care in Great Britain
13. Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection
14. Humoral response to natural influenza infection in solid organ transplant recipients
15. Robust and sensitive amplicon-based whole-genome sequencing assay of respiratory syncytial virus subtype A and B
16. Optimizing mood prior to influenza vaccination in older adults: A three-arm randomized controlled trial.
17. A Double-Blind, Randomized Trial of High-Dose vs Standard-Dose Influenza Vaccine in Adult Solid-Organ Transplant Recipients
18. High attack rate in a large care home outbreak of SARS-CoV-2 BA.2.86, East of England, August 2023
19. Comparison of mucosal lining fluid sampling methods and influenza-specific IgA detection assays for use in human studies of influenza immunity
20. Forecasting the 2017/2018 seasonal influenza epidemic in England using multiple dynamic transmission models: a case study
21. Post-pandemic development of sentinel surveillance of respiratory disease, in the context of the WHO mosaic framework: protocol for the English primary care network 2023-2024 (Preprint)
22. Postpandemic Sentinel Surveillance of Respiratory Diseases in the Context of the World Health Organization Mosaic Framework: Protocol for a Development and Evaluation Study Involving the English Primary Care Network 2023-2024 (Preprint)
23. Humoral, T-cell and B-cell immune responses to seasonal influenza vaccine in solid organ transplant recipients receiving anti-T cell therapies
24. Author Correction: Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection
25. ADCC:An underappreciated correlate of cross-protection against influenza?
26. A case of swine influenza A(H1N2)v in England, November 2023.
27. Persistence and avidity maturation of antibodies to A(H1N1)pdm09 in healthcare workers following repeated annual vaccinations
28. Haemagglutination inhibition and virus microneutralisation serology assays: use of harmonised protocols and biological standards in seasonal influenza serology testing and their impact on inter-laboratory variation and assay correlation: A FLUCOP collaborative study
29. Cross-reactive immunity against influenza viruses in children and adults following 2009 pandemic H1N1 infection
30. Correlates of Protection Against Influenza
31. An external quality assessment feasibility study; cross laboratory comparison of haemagglutination inhibition assay and microneutralization assay performance for seasonal influenza serology testing: A FLUCOP study
32. ADCC: An underappreciated correlate of cross-protection against influenza?
33. Coadministration of Seasonal Influenza Vaccine and MVA-NP+M1 Simultaneously Achieves Potent Humoral and Cell-Mediated Responses
34. A Haemophilus sp. dominates the microbiota of sputum from UK adults with non-severe community acquired pneumonia and chronic lung disease
35. Administration of AS03 B -adjuvanted A(H1N1)pdm09 Vaccine in Children Aged
36. T-Helper 1 Cells Elicited by H5N1 Vaccination Predict Seroprotection
37. H1N1 Antibody Persistence 1 Year After Immunization With an Adjuvanted or Whole-Virion Pandemic Vaccine and Immunogenicity and Reactogenicity of Subsequent Seasonal Influenza Vaccine: A Multicenter Follow-on Study
38. Genomic Investigations of Acute Hepatitis of Unknown Aetiology in Children
39. Validation of a Harmonized Enzyme-Linked-Lectin-Assay (ELLA-NI) Based Neuraminidase Inhibition Assay Standard Operating Procedure (SOP) for Quantification of N1 Influenza Antibodies and the Use of a Calibrator to Improve the Reproducibility of the ELLA-NI With Reverse Genetics Viral and Recombinant Neuraminidase Antigens: A FLUCOP Collaborative Study
40. Humoral Response to the Influenza A H1N1/09 Monovalent AS03-Adjuvanted Vaccine in Immunocompromised Patients
41. Fast Rise of Broadly Cross-Reactive Antibodies after Boosting Long-Lived Human Memory B Cells Primed by an MF59 Adjuvanted Prepandemic Vaccine
42. Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines
43. Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial
44. The immunogenicity of a novel A (H1N1) vaccine in HIV-infected children
45. Immunogenicity and safety of a two-dose schedule of whole-virion and AS03 A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial
46. Humoral and Cellular Immunity to Primary H1N1 Infection in Patients with Hematologic Malignancies following Stem Cell Transplantation
47. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study
48. SARS Antibody Testing in Children: Development of Oral Fluid Assays for IgG Measurements
49. Antibody Persistence after Primary Sars-Cov-2 Infection and Protection Against Future Variants Including Omicron in Adolescents: National, Prospective Cohort Study
50. Neutralising antibody activity against SARS-CoV-2 variants, including Omicron, in an elderly cohort vaccinated with BNT162b2
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.